Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00468143 · ClinicalTrials.gov registry record · Phase 4

A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall

A Phase 4 study of Attention Deficit Hyperactivity Disorder, sponsored by NYU Langone Health.

Completed
Registry status
Phase 4
Development phase
62
Enrollment target
1
Study location

NCT00468143: Completed Phase 4 study of Attention Deficit Hyperactivity Disorder, sponsored by NYU Langone Health.

NCT00468143 is a Phase 4 study of Attention Deficit Hyperactivity Disorder that has completed, run by NYU Langone Health. The registered enrollment target is 62 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00468143, a Phase 4 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
Phase 4
Development phase
62 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pilot study is to compare Adderall ® and Adderall XR ® in terms of their effectiveness and side effects for the treatment of ADHD in adults.

Primary Outcome

Dosage adherence (MEMSd) is the number of bottle openings divided by number of doses prescribed. Adherence was measured as ≥ 75% of the doses. The number below is the total percentage of subjects who were adherent.

Conditions Studied

Attention Deficit Hyperactivity Disorder

Interventions

  • DRUG Adderall ® Immediate Release
  • DRUG Adderall XR ®

Study Locations (1)

New York

  • VANYHHS - New York

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2007-08
Est. Completion 2009-01
Phase Phase 4
NYU Langone Health

1,164 total trials

What the finished NCT00468143 record still lists

NCT00468143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (71% lower).

The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Adderall ® Immediate Release is the first listed.

NCT00468143 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00468143 about?

NCT00468143 is a clinical study titled "A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall". The purpose of this pilot study is to compare Adderall ® and Adderall XR ® in terms of their effectiveness and side effects for the treatment of ADHD in adults.

What is the current status of trial NCT00468143?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2007-08. Estimated completion is 2009-01.

What conditions does trial NCT00468143 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.

What interventions are being tested in trial NCT00468143?

The interventions under investigation include: Adderall ® Immediate Release (DRUG), Adderall XR ® (DRUG).

Who is sponsoring clinical trial NCT00468143?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00468143 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00468143's enrollment target sits among peer trials

62 56th of 102 higher than 45 of 102 other Attention Deficit Hyperactivity Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00468143, the US trial registry maintained by the National Library of Medicine. NCT00468143 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.